Longeveron's Stem Cell Therapy Fails Pediatric Heart Trial, Triggers Cost Cuts
- Longeveron's Phase 2b ELPIS II trial tested laromestrocel, a mesenchymal stem cell therapy, as an add-on to Stage 2 palliative surgery in 40 infants with hypoplastic left heart syndrome (HLHS), a rare, severe congenital heart defect.
- The trial missed its primary endpoint: at 12 months, right ventricular ejection fraction did not improve meaningfully in treated infants versus controls.
- No new safety signals emerged; treated infants had numerically fewer deaths than controls over 12 months — reassuring, but not a substitute for the missed efficacy signal.
- Following the miss, Longeveron said it will cut costs, is "exploring all options" for the program and company strategy, and plans further FDA discussions.
- Shares fell sharply in premarket trading after the announcement.
This is another entry in cell therapy's uneven ledger: mesenchymal stem cell candidates have repeatedly stumbled in small, underpowered pediatric and rare-disease trials, and a 40-patient study was never going to generate a statistically bulletproof efficacy case either way. The "numerically fewer deaths" framing is a familiar move — a directionally encouraging but non-significant number, worth reading as reassurance on safety, not as a rescue for the missed primary endpoint. More telling is the language around cost cuts and "exploring all options": for a small-cap with a thin, concentrated pipeline built largely around laromestrocel, that's the standard prelude to a strategic pivot — partnering out remaining assets, a reverse merger, or a slow wind-down — rather than business as usual. Investors should expect the MSC therapy category's credibility gap with capital markets to widen further on this news.
Longeveron's phase 2b stem cell flop spurs cost cutting, exploration of 'all options' ↗